NNNN — Anbio Biotechnology Class A Ordinary Shares stock price, charts and financials

QT25Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
10.63
+0.02+0.24%
NNNNQT25Anbio Biotechnology Class A Ordinary Shares·NASDAQ
10.63+0.24%
TA
Loading chart...
Screen all →
Snapshot
Index-P/E54.86EPS (ttm)0.19Insider Own-Shs Outstand43.89MPerf Week7.17%
Market Cap465.69MForward P/E-EPS next Y-Insider Trans-Shs Float39.69MPerf Month-4.84%
Enterprise Value457.92MPEG0.55EPS next Q-Inst Own-Short Float0.08%Perf Quarter-59.00%
Income8.48MP/S39.55EPS this Y-Inst Trans-Short Ratio0.88Perf Half Y-55.90%
Sales11.78MP/B15.44EPS next Y-ROA28.07%Short Interest31.58KPerf YTD-64.72%
Book/sh-P/C0.00EPS next 5Y-ROE27.49%52W High55.08 -80.69%Perf Year-76.18%
Cash/sh-P/FCF0.00EPS past 3/5Y31.98% -ROIC25.46%52W Low8.32 27.83%Perf 3Y-
Dividend Est.-EV/EBITDA70.70Sales past 3/5Y-27.89% -Gross Margin86.10%Volatility17.34% 15.55%Perf 5Y-
Dividend TTM-EV/Sales38.89EPS Y/Y TTM239.29%Oper. Margin65.20%ATR (14)1.82Perf 10Y-
Dividend Ex-Date-Quick Ratio344.31Sales Y/Y TTM50.00%Profit Margin72.09%RSI (14)44.00Recom-
Dividend Gr. 3/5Y-Current Ratio344.31EPS Q/Q-SMA206.26%Beta0.14Target Price-
Payout0.00%Debt/Eq0.00Sales Q/Q-16.67%SMA50-28.58%Rel Volume1.24Prev Close10.61
Employees27LT Debt/Eq-EarningsJul 07SMA200-55.47%Avg Volume40.33KPrice10.63
IPO DateFeb 19, 2025Option/ShortYes / YesEPS/Sales Surpr.-Net Debt/EBITDA-1.20Volume50,195Change0.24%
Latest News
Company

Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
Total Revenue1298
Cost of Goods Sold Incl. D&A112
Gross Profit1186
Selling, General and Administrative Excl. Other223
Research and Development
000
Other Operating Expense001
Operating Income862
Interest Expense
000
Unusual Expense
Non-Operating Income (Expense)010
Net Income Before Taxes862
Income Taxes
000
Consolidated Net Income862
Net Income From Continuing Operations862
Net Income862
EPS (Recurring)0.190.160.06
EPS (Basic, Before Extraordinaries)0.190.160.06
EPS (Diluted)0.190.160.06
EBITDA762
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio55.97187.94
Price To Sales Ratio39.00147.01
Gross Margin91.6788.8975.00
Operating Margin66.6766.6725.00
Net Margin66.6766.6725.00
Shares Outstanding444442
Market Capitalization4681,323
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.